ABSTRACT Restorative treatment is very challenging for non-carious cervical lesions (NCCLs) due to functional and structural complexities. The purpose of this randomised controlled trial (RCT) was to evaluate the clinical performance of nanocomposite restorations bonded using universal adhesive in self-etch mode with and without air abrasive surface treatment for NCCLs. A total of 70 NCCLs, from a group of consenting patients who fulfilled the inclusion criteria, were recruited for the study. The study was carried out following CONSORT guidelines. Block randomisation was done for equal allocation of lesions into; Group 1 (surface treatment with alumina air abrasion) and Group 2 (control group without mechanical surface treatment). The lesions were restored with nanocomposite using a universal bonding agent in self-etch mode. The clinical performance of the restorations was evaluated by two examiners using modified United States Public Health Service (USPHS) criteria at baseline, 3 months, 6 months and 12 months. A Chi-square test was performed for inter-group comparison. Cochran’s Q test and Dunn’s post hoc analysis were used for intra-group comparison. The inter-group comparison revealed no statistically significant difference between the experimental and control group for all the parameters assessed. With the intra-group analysis, it was found that there was a significant decrease in the performance of the restorations concerning marginal staining, marginal adaptation and surface texture during the evaluation period (p < 0.05). However, all of them demonstrated clinically acceptable performance. According to the results of this RCT, it was concluded that airborne particle abrasion of NCCLs did not improve the clinical performance of nanocomposite resin bonded using universal adhesive.
Composite Resins ; Air Abrasion, Dental

Background: and Purpose Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. Methods: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). Results: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. Conclusions During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.